PRAME - Wikipedia PRAME (preferentially expressed antigen of melanoma) is a protein that in humans is encoded by the PRAME gene [3][4][5] Five alternatively spliced transcript variants encoding the same protein have been observed for this gene
PRAME Expression in Melanocytic Tumors - PMC PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen that was isolated by autologous T cells in a melanoma patient While frequent PRAME mRNA expression is well documented in cutaneous and ocular melanomas, little is
PRAME Expression in Melanocytic Tumors - PubMed In this study we examined the immunohistochemical expression of PRAME in 400 melanocytic tumors, including 155 primary and 100 metastatic melanomas, and 145 melanocytic nevi Diffuse nuclear immunoreactivity for PRAME was found in 87% of metastatic and 83 2% of primary melanomas
PRAME – MyPathologyReport PRAME stands for “preferentially expressed antigen in melanoma ” It is a special type of protein called a cancer-testis antigen This means that PRAME is usually found in cancer cells and normal cells within the testis, but rarely in other normal tissues of the body
The Role of PRAME in Malignant Melanoma: From Biomarker to Therapeutic . . . PRAME emerges as a promising biomarker and therapeutic target in malignant melanoma, offering avenues for improved diagnosis, prognostication, and treatment Its pivotal roles in driving disease progression underscore its significance in malignant melanoma pathogenesis
PRAME Expression in Cancer. A Systematic Immunohistochemical Study of . . . Preferentially expressed antigen in melanoma (PRAME) is considered a useful marker in the differential diagnosis between malignant melanoma and its melanocytic mimics Recently PRAME expression was documented in nonmelanocytic tumors, but much of the data are based on mRNA studies
How Useful Is PRAME Testing in Choroidal Melanoma? Preferentially expressed antigen in melanoma, or PRAME, is a cancer-test antigen that is overexpressed in melanoma and is typically a marker of poor outcomes Up first, Zélia M Corrêa, MD, PhD, explained why she favors testing for PRAME Improved prognostic testing accuracy